Molecular Templates, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Income (Loss) Per Common Share (Tables)

Net Income (Loss) Per Common Share (Tables)

9 Months Ended

Sep. 30, 2014

Reconciliation of Numerator and Denominator

A reconciliation of the numerator and denominator used in the calculation is as follows (in thousands, except per share amounts):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2014			2013			2014			2013
Numerator:
Net income (loss) - basic	$	(7,745	)	$	1,176		$	(15,620	)	$	(20,826	)
Less: noncash income from change in fair value of common stock warrants		(1,558	)		(6,379	)		(7,781	)		(557	)

Net loss - diluted		(9,303	)		(5,203	)		(23,401	)		(21,383	)

Denominator:
Weighted average common shares outstanding		59,845			58,542			59,500			57,362
Dilutive effect of warrants		1,649			5,019			3,919			2,509

Weighted-average common shares outstanding and dilutive potential common shares — diluted		61,494			63,561			63,419			59,871

Net income (loss) per share
Basic	$	(0.13	)	$	0.02		$	(0.26	)	$	(0.36	)
Diluted	$	(0.15	)	$	(0.08	)	$	(0.37	)	$	(0.36	)

Warrants, Options and Purchase Rights Excluded from Computation of Diluted Net Loss Per Share

The following outstanding warrants, options and purchase rights under the Company’s 2004 Employee Stock Purchase Plan were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an antidilutive effect (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
Shares issuable upon exercise of warrants		649		—		—		4,034
Shares issuable upon exercise of stock options		8,173		6,560		8,173		6,560
Shares issuable related to the ESPP		33		28		33		28